$377 Million is the total value of CHI Advisors LLC's 24 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 39.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RXDX | Buy | PROMETHEUS BIOSCIENCES INC | $100,251,367 | -1.3% | 934,135 | +1.1% | 26.61% | -1.7% |
| PLRX | Sell | PLIANT THERAPEUTICS INC | $79,848,812 | +30.3% | 3,001,835 | -5.3% | 21.20% | +29.9% |
| VECT | Sell | VECTIVBIO HLDG AG | $44,724,170 | -6.0% | 5,255,484 | -4.3% | 11.87% | -6.3% |
| CGEM | Buy | CULLINAN ONCOLOGY INC | $34,264,977 | -2.1% | 3,349,460 | +1.0% | 9.10% | -2.4% |
| RPTX | Buy | REPARE THERAPEUTICS INC | $29,499,719 | -28.4% | 2,997,939 | +7.1% | 7.83% | -28.6% |
| LRMR | Sell | LARIMAR THERAPEUTICS INC | $12,440,580 | -13.3% | 2,746,265 | -20.9% | 3.30% | -13.6% |
| KROS | Buy | KEROS THERAPEUTICS INC | $11,147,219 | +7.9% | 261,059 | +21.4% | 2.96% | +7.6% |
| CMPX | COMPASS THERAPEUTICS INC | $9,253,158 | -35.0% | 2,829,712 | 0.0% | 2.46% | -35.2% | |
| Buy | 2SEVENTY BIO INC | $8,721,000 | +179.3% | 855,000 | +156.6% | 2.32% | +178.2% | |
| INZY | Sell | INOZYME PHARMA INC | $7,690,754 | +232.2% | 1,342,191 | -39.1% | 2.04% | +231.0% |
| OMEGA THERAPEUTICS INC | $6,366,969 | +5.6% | 1,055,882 | 0.0% | 1.69% | +5.2% | ||
| IKNA | Buy | IKENA ONCOLOGY INC | $5,730,010 | +31.6% | 1,660,872 | +1.4% | 1.52% | +31.1% |
| Buy | RALLYBIO CORP | $4,342,701 | -9.0% | 760,543 | +4.7% | 1.15% | -9.3% | |
| New | ORCHARD THERAPEUTICS PLCspon ads new | $4,219,414 | – | 785,738 | +100.0% | 1.12% | – | |
| KDNY | New | CHINOOK THERAPEUTICS INC | $3,125,250 | – | 135,000 | +100.0% | 0.83% | – |
| DTIL | Sell | PRECISION BIOSCIENCES INC | $2,614,857 | -38.1% | 3,469,820 | -2.3% | 0.69% | -38.3% |
| OVID | OVID THERAPEUTICS INC | $2,231,241 | +38.7% | 864,822 | 0.0% | 0.59% | +38.3% | |
| KZR | Sell | KEZAR LIFE SCIENCES INC | $2,157,982 | -83.8% | 689,451 | -63.5% | 0.57% | -83.8% |
| FRLN | Sell | FREELINE THERAPEUTICS HLDGSsponsored ads | $2,151,886 | -5.9% | 4,729,419 | -1.8% | 0.57% | -6.2% |
| CRVS | Sell | CORVUS PHARMACEUTICALS INC | $2,128,856 | +5.0% | 2,339,402 | -1.9% | 0.56% | +4.6% |
| New | SYROS PHARMACEUTICALS INC | $2,049,078 | – | 767,445 | +100.0% | 0.54% | – | |
| New | ENTRADA THERAPEUTICS INC | $817,423 | – | 56,374 | +100.0% | 0.22% | – | |
| ONCR | ONCORUS INC | $814,634 | +35.8% | 2,367,436 | 0.0% | 0.22% | +35.0% | |
| RXDX | New | PROMETHEUS BIOSCIENCES INCcall | $108,125 | – | 25,000 | +100.0% | 0.03% | – |
| PLRX | Exit | PLIANT THERAPEUTICS INCcall | $0 | – | -30,000 | -100.0% | -0.01% | – |
| LABD | Exit | DIREXION SHS ETF TRdaily s&p biotec | $0 | – | -25,000 | -100.0% | -0.12% | – |
| GTHX | Exit | G1 THERAPEUTICS INC | $0 | – | -333,945 | -100.0% | -0.48% | – |
| ORTX | Exit | ORCHARD THERAPEUTICS PLCspon ads | $0 | – | -7,987,396 | -100.0% | -0.79% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-11
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| PRECISION BIOSCIENCES INC | 17 | Q3 2023 | 13.4% |
| OVID THERAPEUTICS INC | 17 | Q3 2023 | 5.8% |
| CORVUS PHARMACEUTICALS INC | 16 | Q2 2023 | 1.8% |
| KEZAR LIFE SCIENCES INC | 15 | Q1 2023 | 5.8% |
| PLIANT THERAPEUTICS INC | 14 | Q3 2023 | 29.2% |
| REPARE THERAPEUTICS INC | 14 | Q3 2023 | 30.3% |
| ORCHARD THERAPEUTICS PLC | 14 | Q4 2022 | 52.6% |
| LARIMAR THERAPEUTICS INC | 14 | Q3 2023 | 9.1% |
| KEROS THERAPEUTICS INC | 14 | Q3 2023 | 8.6% |
| INOZYME PHARMA INC | 13 | Q3 2023 | 9.4% |
View CHI Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Corvus Pharmaceuticals, Inc. | February 13, 2023 | 2,384,402 | 5.1% |
| Cullinan Oncology, Inc. | February 13, 2023 | 3,317,544 | 7.2% |
| Freeline Therapeutics Holdings plc | February 13, 2023 | 4,814,419 | 7.4% |
| Inozyme Pharma, Inc. | February 13, 2023 | 2,204,876 | 5.5% |
| Larimar Therapeutics, Inc. | February 13, 2023 | 3,473,366 | 8.0% |
| Oncorus, Inc. | February 13, 2023 | 2,367,436 | 9.1% |
| Orchard Therapeutics plc | February 13, 2023 | 7,987,396 | 6.3% |
| PLIANT THERAPEUTICS, INC. | February 13, 2023 | 3,199,892 | 6.6% |
| Repare Therapeutics Inc. | February 13, 2023 | 2,800,126 | 6.7% |
| VectivBio Holding AG | February 13, 2023 | 5,492,893 | 8.8% |
View CHI Advisors LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-11-13 |
| 13F-HR/A | 2023-08-22 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-11 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
View CHI Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.